e-therapeutics plc
("e-therapeutics" or "the Company")
Notification of Full Year Results Date
Oxford, UK, 27 April 2022 - e-therapeutics plc (AIM: ETX; OTCQX: ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, will announce its full year audited results for the year ended 31 January 2022 on Wednesday 4 May 2022.
Enquiries:
e-therapeutics plc |
|
Ali Mortazavi, CEO James Chandler, VP IR & Strategic Communications |
Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk |
|
|
|
|
SP Angel Corporate Finance LLP
|
Tel: +44(0)20 3470 0470 |
Nominated Adviser and Broker
|
|
Matthew Johnson/Caroline Rowe (Corporate Finance)
|
|
Vadim Alexandre/Rob Rees (Corporate Broking) |
|
|
|
About e-therapeutics plc
e-therapeutics plc is a UK-based company integrating computational power and biology to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.
The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.